Investment
Features
FeesSafety
Academy
More
Pluang+

Compare e l f Beauty Inc (ELF) vs Eli Lilly And Co (LLY) Price & Performance

e l f Beauty IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

e l f Beauty Inc vs Eli Lilly And Co — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while Eli Lilly And Co trades at $1,162.56 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 171× e l f Beauty Inc's market cap, and Eli Lilly And Co pays a 0.58% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Eli Lilly And Co for 93 Days on average.

ELFLLY
Market Cap
$6.20B$1.06T
Volume
1,301,2402,297,239
Sector
Consumer StaplesHealth
52-Week High
$144.97$1.28K
52-Week Low
$49.57$799.57
Typical Hold Time
25 Days93 Days
Enterprise Value
$6.78B$1.11T
Dividend Yield
—0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

e l f Beauty Inc

ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.

The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.

Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ELF

No sentiment data available yet.

LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About e l f Beauty Inc

e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.

Read more on ELF →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →